Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Anlotinib, and Nab-paclitaxel in Resectable Stage II-III NSCLC
NCT07089199Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, anlotinib, paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Qilu Hospital of Shandong University. Started Jul 2025; status: recruiting.
02
Drugs
tislelizumabanlotinibpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07089199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089199.